Drug Type Bispecific antibody |
Synonyms- |
Target |
Mechanism CD40 inhibitors(Tumor necrosis factor receptor superfamily member 5 inhibitors), PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colonic Cancer | Preclinical | CN | 02 Nov 2023 | |
Melanoma | Preclinical | CN | 02 Nov 2023 |